Rosmantuzumab Overview

Introduction of Rosmantuzumab

Rosmantuzumab, also known as OMP-131R10, is a specially engineered monoclonal antibody designed to target the R-spondin 3 (RSPO3) protein. RSPO3, a member of the R-spondin family, plays a significant role in the modulation of the Wnt signaling pathways. By binding to RSPO3, rosmantuzumab inhibits its interaction with corresponding receptors such as LGR4, LGR5, and LGR6, thereby curtailing the aberrant activation of the Wnt/β-catenin signaling pathway—a processs extensively implicated in various cancers. Initially developed by OncoMed Pharmaceuticals, rosmantuzumab is currently being investigated for its potential in treating cancers associated with abnormal Wnt signaling, particularly colorectal cancer and other solid tumors.

Biological and Chemical Properties of Rosmantuzumab

Protein Structure

Figure 1. The Structure of Human R-spondin-3 (UniProt)^1,2

Protein Chemical Formula

C₆₄₅₆H₉₉₅₄N₁₇₁₄O₂₀₄₈S₄₆

The Mechanism of Rosmantuzumab Action

RSPO3 is one of four members of the R-spondin family, a group of secreted proteins crucial for enhancing Wnt signaling. RSPO3 interacts with leucine-rich repeat-containing G-protein coupled receptors (LGRs) such as LGR4, LGR5, and LGR6. This interaction activates both the canonical Wnt/β-catenin pathway and non-canonical pathways. Normally, RSPO3 stabilizes the Frizzled/LRP5/6 receptor complexes on the cell surface, facilitating the accumulation and translocation of β-catenin to the nucleus. β-catenin then activates the transcription of Wnt target genes involved in cellular proliferation, differentiation, and stem cell renewal. In disease states, particularly in oncology, the overexpression or dysregulation of RSPO3 is linked to the aberrant activation of the Wnt signaling pathway. Continuous activation of this pathway results in uncontrolled cell proliferation, inhibition of apoptosis, and tumorigenesis. Enhanced RSPO3 expression has been identified in colorectal, ovarian, and other solid tumors, making it a critical target for therapeutic intervention.

Rosmantuzumab exerts its anti-cancer effects by neutralizing RSPO3 activity. The antibody binds to RSPO3 with high specificity and affinity, preventing RSPO3 from interacting with its receptors, LGR4, LGR5, and LGR6. By sequestering RSPO3, rosmantuzumab inhibits the formation of the Frizzled/LRP5/6 receptor complex. This inhibition disrupts the downstream Wnt/β-catenin signaling pathway, blocking the translocation of β-catenin to the nucleus and reducing the transcription of Wnt target genes. Consequently, this blockade leads to decreased cellular proliferation.

Figure 2. WNT/β-catenin Signaling Pathway and The Mechanism of Rosmantuzumab Action^3,4

Clinical Projects of Rosmantuzumab*

* The table was excerpted from the following website: https://clinicaltrials.gov/search?cond=OMP-131R10

What We Provide

Rosmantuzumab

Anti-Human RSPO3 Recombinant Antibody (Rosmantuzumab)

We provide high-quality rosmantuzumab for use in ELISA, IHC, FC, IP, IF, and FuncS. The product is intended for lab research use only, not for diagnostic, therapeutic, or any in vivo human applications.

SpecificationTested Data

• Immunogen
• The details of the immunogen for this antibody are not available.

• Host Species
• Human

• Derivation
• Humanized

• Type
• IgG1, κ

• Specificity
• Human RSPO3

• Species Reactivity
• Human

• Applications
• ELISA, IHC, FC, IP, IF, FuncS

• Conjugate
• Unconjugated

• CAS
• 1684393-04-1

• Generic Name
• Rosmantuzumab

• UNII
• VD026R6TCI

• Related Disease
• Advanced Relapsed Tumor, Refractory Solid Tumors

View more details

SDS-PAGE

Figure 1 Anti-Human RSPO3 Recombinant Antibody (TAB-449CQ) in SDS-PAGE

Lane 1: 2 μg, Non-Reducing mAb Lane 2: 2 μg, Reducing mAb

For research use only. Not intended for any clinical use.